



Sarah Ruiz - Senior Director, Product Management Operations - Vial

Krystyna Kowalczyk - Chief Executive Officer - Kapadi

Chris O'Brien – Chief Executive Officer – Biorasi

Adam Hamm - SVP, Biostatistics & Strategic Consulting - SDC

Colin Hayward - Head of Medical Science - ERGOMED

Catherine Gregor - Chief Clinical Trial Officer - Florence Healthcare

Chris Learn - Vice President, Cell & Gene Therapy - Parexel

Hiroki Matsushima - Branch Manager, US - A2 Healthcare

Abhishek Gupta – Senior Vice President, Head of Cell & Gene Therapy – Syneos Health

Jasmina Jankicevic - Chief Medical Officer - Innovaderm Research

Steve Chriscoe - Vice President, Oncology Project Management - Worldwide Clinical Trials

Tomasz Bartlomiejski - CRA Resourcing Manager, Clinical Operations - Stiris Research

Vatche Bartekian – President – Vantage Biotrials

Kirk Wroblewski - Chief Information Officer - Propharma

TBC - AG Mednet

Jin Dai - Chief Operating Officer - Everest Clinical Research

Sybil Wilson - Senior Director, Integrated Clinical Solutions - Veristat

Paul Johnson - Executive Director, Strategy Development - PharPoint Research

Cassandra Erato - Chief Executive Officer - Spaulding Clinical

Earl Seltzer - Senior Director, Therapeutic Strategy & Innovation - CTI Clinical Trial & Consulting

TBC - Mednet

**TBC - Endpoint Clinical** 

TBC - TRYAL

TBC - **H1** 

#### Register to attend

https://www.thepbcgroup.com/crosummit-registration

#### **Contact Information**

Content - David Jones djo@thepbcgroup.com

Attendance - Alexander O'Leary aol@thepbcgroup.com

Venue/ Ops – Samantha Drewe sam@thepbcgroup.com





#### Day 1: 3rd December 2024

08:00 - Registration & Morning Refreshments

08:55

08:55 Welcome Address

Jasmina Jankicevic - Chief Medical Officer - Innovaderm Research

**SECTION A** 

Collaboration

09:00 Opening Keynote

Fostering Effective Collaboration Between Sponsor and CRO

Exploring strategies to optimize collaboration between a sponsor and CROs. Discussing how to establish well-defined delivery plans, streamline communication methods, build cohesive teams, and set clear deliverables.

In this session Steve will share real-world examples of challenges faced from his Biopharma & CRO experiences and provide practical solutions to overcome them. Providing insights to enhance working relationships and drive successful trial outcomes.

Steve Chriscoe - Vice President, Oncology Project Management - Worldwide Clinical Trials

09:25 Keynote

Leveraging Technology for Seamless Collaboration Across Distributed Teams

In today's globalized clinical research landscape, effective collaboration among teams across multiple locations, sponsors, sites, and vendors is paramount. Automating mission-critical trial workflows and processes are giving trial sponsor and CRO operational teams an advantage on reducing workflow friction, harnessing AI to enhance data quality through computer-assisted redaction of PHI, early identification of bottlenecks, and real-time study progress visibility.

In this session Catherine from Judi, will share how CROs, Trial Sponsors, and Sites harness these tools to streamline processes, enhance transparency, ensure stronger regulatory compliance, and improve data quality.

TBC - AG Mednet

09:50 Keynote

Harnessing CRO's Therapeutic Expertise to Accelerate Trial Delivery

CROs possess invaluable internal therapeutic area expertise that can significantly accelerate trial delivery when effectively utilized. Exploring how sponsors can leverage their CRO's therapeutic lead to identify key opinion leaders, select the most suitable clinical trial sites, and determine the optimal geography for trial launch.





## Clinical Outsourcing Group: CRO Summit

# Raleigh Marriott City Centre, North Carolina 3<sup>rd</sup> & 4<sup>th</sup> December 2024

In this session, Jasmina will discuss strategies for maximizing the impact of therapeutic expertise, enhancing decision-making processes, and ultimately accelerating the delivery of clinical trials. Bridging the gap between CRO knowledge and execution to achieve optimal results.

Jasmina Jankicevic - Chief Medical Officer - Innovaderm Research

10:15 Panel

Collaboration: Q&A Panel Discussion

This interactive Q&A session provides a unique opportunity to engage directly with this section's presenters, gain further perspectives, and explore challenges facing CROs and trial sponsors with regards to collaboration.

10:45 Coffee Break

#### **SECTION B**

**Technology Integration** 

11:15 Keynote

The Digital Revolution: Your Guide to Digitalizing Clinical Trials

Digitalization is playing a pivotal role in transforming the way we approach endpoint measurement, study design, and patient engagement. Navigating regulatory requirements while prioritizing the needs of patients and sites.

In this session Sarah will explore how to effectively leverage technology to bring clinical trials into the digital world, focusing on the vast opportunities presented by digital and decentralized clinical trials (DCTs). Emphasizing the importance of streamlining and optimizing processes for patients, sites, and CROs to support the use of technology, ensuring it serves as an enabler rather than a hindrance.

Sarah Ruiz - Senior Director, Product Management Operations - Vial

11:40 Keynote

Session Details To Be Confirmed

Adam Hamm - SVP, Biostatistics & Strategic Consulting - SDC

12:05 Keynote

Winning Together Case Study: CRO and Vendor Partnerships

In an increasingly competitive landscape, CROs must explore innovative strategies to differentiate themselves and secure clinical trial contracts. One powerful approach is to forge strategic alliances with Functional Service Providers (FSPs) and technology vendors.

In this session Jin we will discuss how CROs can effectively collaborate with external partners to demonstrate cost savings, operational efficiency, and cutting-edge capabilities through technology





## Clinical Outsourcing Group: CRO Summit

# Raleigh Marriott City Centre, North Carolina 3<sup>rd</sup> & 4<sup>th</sup> December 2024

integration. Sharing real-world examples of Everest's successful CRO-vendor alliances, highlighting the key factors that contribute to winning bids.

Jin Dai – Chief Operating Officer – Everest Clinical Research

#### 12:30 Pane

**Technology Integration: Q&A Panel Discussion** 

This interactive Q&A session provides a unique opportunity to engage directly with this section's presenters, gain further perspectives, and explore challenges facing CROs and trial sponsors with regards to technology integration.

#### 1:00 **Lunch**

#### **SECTION C**

Vendor Alliances

#### 2:00 Keynote

#### Mastering Audit Readiness: Preventing Common Issues in Clinical Trials

Effective audit preparation is crucial for CROs to maintain compliance and ensure the integrity of clinical trials. Identifying common audit findings and implementing preventive measures are key to successful trial management.

In this session, Vatche we will explore proven strategies for identifying potential audit issues, implementing robust quality management systems, and fostering a culture of continuous improvement within CROs. Navigate common audit challenges, optimize quality assurance processes, and establish clear protocols to keep all aspects of clinical trials audit-ready.

Vatche Bartekian - President - Vantage Biotrials

#### 2:25 Keynote

## Winning Bids with Cutting-Edge Technology: A Case Study on SDC and Mednet's Collaboration

Showcasing how CROs can gain a competitive edge in winning bids by leveraging the powerful collaboration with the example of SDC and Mednet. Discovering how Mednet's highly flexible, efficient, and comprehensive clinical data management system, centered around a robust Electronic Data Capture (EDC), can revolutionize your clinical trials.

In this session XXX will share how Mednet's solution has provided SDC with a wide range of capabilities, including randomization, supply management, adjudication, ePRO, payments, and DICOM imaging, making it adaptable to various study types and designs. Sharing examples of how this collaboration has empowered CROs, like SDC, to streamline processes, enhance data quality, and deliver exceptional results to trial sponsors.

#### **Reserved for Mednet**





# Clinical Outsourcing Group: CRO Summit Raleigh Marriott City Centre, North Carolina

3<sup>rd</sup> & 4<sup>th</sup> December 2024

2:50 Keynote

## Seats at the Table: Collaborative Strategies for Competitors in Large-Scale Clinical Trial Outsourcing

In today's complex landscape of clinical trial operations, sponsors often engage multiple competing CROs to support large-scale development projects. This approach, while leveraging diverse expertise, presents unique challenges in aligning competitors towards shared client goals.

In this session, Earl will explore innovative strategies for fostering productive collaboration among CROs within projects and across multiple opportunities. Drawing from real-world experiences, presenting methods for establishing a cooperative framework that maintains competitive integrity while prioritizing client objectives. Key topics will include creating transparent communication channels, defining clear roles and responsibilities, and ensuring all parties have a meaningful "seat at the table" in driving successful clinical trial outcomes.

Earl Seltzer - Senior Director, Therapeutic Strategy & Innovation - CTI Clinical Trial & Consulting

3:15 Panel

Vendor Alliances: Q&A Panel Discussion

This interactive Q&A session provides a unique opportunity to engage directly with this section's presenters, gain further perspectives, and explore challenges facing CROs and trial sponsors with regards to the overall CRO market.

3:45 Coffee Break

#### **SECTION D**

**Budgeting, Contracting & Forecasting** 

4:15 Keynote

#### Mastering Budget Management for Clinical Trial Profitability & Transparency

Effective budget management is essential for CROs to maintain profitability and ensure the financial viability of trials. Detailing best practices for risk assessment, financial forecasting, and proactive budget adjustments

In this session Paul will explore proven strategies for building contingencies into trial budgets, predicting future costs, tracking spending, and fostering transparent communication between CRO, sites, and sponsor. Navigating common budgetary challenges, optimize resource allocation, and establish clear lines of communication to keep all stakeholders informed.

Paul Johnson – Executive Director, Strategy Development – PharPoint Research

4:40 Keynote

Session Details To Be Confirmed





# Clinical Outsourcing Group: CRO Summit Raleigh Marriott City Centre, North Carolina

3<sup>rd</sup> & 4<sup>th</sup> December 2024

#### **Reserved for Endpoint**

5:05 Keynote

#### Radiopharmaceutical Clinical Trials: Vendor Engagement, Supply & Logistics

Trials involving Radiopharmaceuticals face several unique challenges, including radiation exposure risk, often short half-lives, and limited patient populations. Investigation into radiopharmaceutical drugs is booming with the market expected to be worth \$13 billion by 2032.

In this session Colin will share his experience when conducting clinical research with radiopharmaceuticals. Providing insight into the unique challenges faced requiring enhanced vendor engagement, as well as specialised IMP supply & logistics.

Colin Hayward - Head of Medical Science - ERGOMED

5:30 Panel

#### **Budgeting, Contracting & Forecasting: Q&A Panel Discussion**

This interactive Q&A session provides a unique opportunity to engage directly with this section's presenters, gain further perspectives, and explore challenges facing CROs and trial sponsors with regards to the overall CRO market.

6:00

#### **Networking Champagne Reception**

(complementary admission to all conference participants)

#### Day 2: 4th December 2024

### 08:00 - Registration & Morning Refreshments 08:30

#### **SECTION E**

Site Relationships

08:30

Keynote C-Suite Panel Discussion

#### Navigating the Future: Strategic Outlook for the CRO Industry

The biopharma landscape is experiencing unprecedented changes, driven by technological advancements, evolving funding models, and shifting healthcare dynamics. CROs are challenged to adapt their strategies to these transformative forces while continuing to deliver innovative therapies and value to patients.

In this session, the panel of CRO executives will examine the impact of AI, discuss emerging funding and payment models, consider the expanding role of pharmacies in trial delivery, and analyze industry-wide consolidation trends. The panel will also explore how these impactful changes are reshaping the landscape for trial delivery.

Chair: Jasmina Jankicevic – Chief Medical Officer – Innovaderm Research Jin Dai – Chief Operating Officer – Everest Clinical Research





## Clinical Outsourcing Group: CRO Summit

# Raleigh Marriott City Centre, North Carolina 3<sup>rd</sup> & 4<sup>th</sup> December 2024

Cassandra Erato – Chief Executive Officer – Spaulding Clinical Sybil Wilson – Senior Director, Integrated Clinical Solutions – Veristat Chris O'Brien – Chief Executive Officer – Biorasi

09:15 Keynote

#### **Leveraging Enablement Technology for Optimal Site Performance**

Clinical study sites are the backbone of successful trials, but often face challenges related to limited resources and process inefficiencies. Discover how innovative tools can reduce bottlenecks during study start-up, improve data quality, and enable sites to focus on what matters most – delivering high-quality patient care and reliable study results.

In this session Catherine will discuss how site enablement technology can be a game-changer in streamlining processes, enhancing reporting, and helping sites achieve more with their available resources. Providing practical insight into implementing site enablement technologies and strategies to maximize site performance and efficiency.

Catherine Gregor - Chief Clinical Trial Officer - Florence Healthcare

09:40 Keynote

#### Cell & Gene Therapy Trials: A Site Collaboration Success Story

As cell and gene therapies continue to push the boundaries of medical innovation, clinical study sites face unique challenges in conducting these specialized trials. Exploring the best practice for site identification in both the US and Europe, ensuring the selection of the most qualified and experienced sites for these cutting-edge studies.

In this session Chris will focus on effective strategies for upskilling clinical study site staff to handle the complexities of cell and gene therapy trials confidently and competently. Expanding into training approaches, site selection criteria, and collaboration techniques to optimize site engagement and performance in the realm of cell and gene therapies.

Chris Learn – Vice President, Cell & Gene Therapy - Parexel

10:05 Panel

Site Relationships: Q&A Panel Discussion

This interactive Q&A session provides a unique opportunity to engage directly with this section's presenters, gain further perspectives, and explore challenges facing CROs and trial sponsors with regards to site relationships.

10:30 Coffee Break

**SECTION F** 

Artificial Intelligence

11:00 Keynote

Harnessing AI and LLMs within Internal CRO Operations





Artificial Intelligence (AI) and Large Language Models (LLMs) have the ability to streamline internal processes within CROs. While off-the-shelf solutions exist, many CROs are choosing to build in-house to maintain control over their data and processes.

In this session Kirk will explore the potential of these technologies to streamline internal processes, drive efficiency, and create value across operations. Sharing the experience in building Al-powered tools inhouse, discussing the potential challenge of data, and the opportunity for a de-risked approach to Al implementation.

Kirk Wroblewski - Chief Information Officer - Propharma

#### 11:25 Keynote

#### **Accelerating Clinical Studies with Al-Powered Smart Tools**

Artificial Intelligence (AI) is revolutionizing the clinical research landscape, offering unprecedented opportunities to accelerate studies, reduce costs, and enhance efficiency. Exploring how innovative solutions can streamline processes, optimize resource allocation, and provide full transparency throughout the study lifecycle.

In this session XXX will showcase TRYAL's cutting-edge AI technologies and smart tools that are transforming the way clinical trials are planned and conducted. Sharing real-world case studies demonstrating the impact of AI on clinical trial speed, cost-effectiveness, and overall performance. Arguing how leveraging AI to drive clinical studies forward and to stay ahead in an increasingly competitive market.

#### Reserved for TRYAL

#### 11:50 Keynote

#### The Reality of Al: Beyond the Hype

Artificial Intelligence has emerged as a transformative force in healthcare, promising revolutionary advancements in patient care, drug discovery, and operational efficiency. The journey from potential to practical implementation is often more complex than headlines suggest, with both successes and challenges that deserve equal attention.

In this session, Tomasz will explore AI in healthcare, balancing hype with practical applications. He'll compare Machine Learning and Generative AI, discussing their potential and risks. Using case studies Tomasz will highlight AI implementation realities, including key success factors such as clear objectives, collaboration, data preparation, and ongoing evaluation.

Tomasz Bartlomiejski - CRA Resourcing Manager, Clinical Operations - Stiris Research

#### 12:15 Panel

#### Artificial Intelligence: Q&A Panel Discussion

This interactive Q&A session provides a unique opportunity to engage directly with this section's presenters, gain further perspectives, and explore challenges facing CROs and trial sponsors with regards to the adoption of Artificial Intelligence.





12:45 Lunch

#### **SECTION G**

Patient Enrolment & Engagement

#### 1:45 Keynote

#### Leveraging High Patient Engagement in Japan & Taiwan for Effective Recruitment

Japan and Taiwan have emerged as powerhouses in clinical research, boasting remarkably high levels of patient engagement and efficient recruitment processes. Exploring the unique landscape of clinical trials in these countries, focusing on how their cultural and healthcare environments contribute to exceptional patient participation rates.

In this session Hiroki will share insights into the factors that enable on-time and often early patient recruitment in these markets. Discussing cultural attitudes towards clinical research, healthcare infrastructure and patient-physician relationships, as well as high-quality data generation.

Hiroki Matsushima – Branch Manager, US – A2 Healthcare

#### 2:10 Keynote

#### Driving Diversity, Equity & Inclusion in Clinical Trials: A Data-Driven Approach

The lack of diversity among principal investigators and patient populations in clinical trials significantly impacts the efficacy of new therapies in real-world settings. This underrepresentation not only undermines global health equity but also introduces unacceptable risks of adverse reactions in different patient cohorts. Moreover, it can jeopardize billions of dollars in research investment.

In this session, H1 will showcase how leveraging comprehensive data and advanced analytics can revolutionize the approach to diversity, equity, and inclusion (DEI) in clinical trials. Sharing strategies for selecting trial sites to improve diversity and health equity, leveraging AI-powered analytics to enhance trial design, and the role of social determinants of health data in building more inclusive trials.

#### Reserved for H1

#### 2:35 Keynote

#### Revolutionizing Patient Access: Broadening the US Clinical Research Landscape

Despite common misconceptions, the US market for clinical research is far from saturated. Researchers often rely on familiar sites, limiting geographical reach and patient diversity. It's time for a paradigm shift in our approach to site selection and patient recruitment. By adopting a more reactive strategy we can dramatically reduce trial recruitment timelines, improve patient access to research, and achieve true diversity in clinical trials.

In this session, Krystyna will challenge traditional site selection and start-up methods, presenting an innovative approach to expanding the clinical research footprint across the United States. Exploring how changing attitudes and embracing a more flexible, patient-centric model can transform the industry.

Krystyna Kowalczyk - Chief Executive Officer - Kapadi





3:00 Closing Panel

Patient Enrolment & Engagement: Q&A Panel Discussion

This interactive Q&A session provides a unique opportunity to engage directly with this section's presenters, gain further perspectives, and explore challenges facing CROs and trial sponsors with regards to budgeting and contracts.

**End of Conference**